Wisp Targets Longevity Gap, Launching Health Suite for Women

NEW YORK, NY – March 10, 2026 – Wisp, the largest women’s telehealth company in the United States, has officially entered the burgeoning longevity market with the launch of its new "Longevity and Healthy Aging" category. The move signals a significant strategic expansion for the company, aiming to correct a market imbalance that has historically prioritized male-centric biohacking over the specific physiological needs of women.

The new vertical debuts with a suite of five science-backed treatments, including glutathione, NAD+, and low-dose naltrexone (LDN), available via nasal spray or injection. These therapies are designed to optimize female biology by enhancing cellular energy, promoting repair, and recalibrating the immune system, all under the guidance of a clinician. This launch positions Wisp not just as a provider of reproductive and sexual health services, but as a comprehensive partner in managing women's long-term wellness, or "healthspan."

A Market That Has Overlooked Women

The expansion comes as a direct response to what Wisp identifies as a critical "longevity gap." While the anti-aging and wellness industry has exploded, its focus has often been on performance enhancement and biohacking trends tailored to a male audience. According to Wisp, this has left women navigating a fragmented and expensive market without clear, credible guidance.

A recent national survey conducted by the company, involving nearly 2,000 women, substantiates this gap. The findings revealed that while a staggering 75 percent of women prioritize their long-term health in daily decisions, nearly half feel uncertain about which health interventions are genuinely effective for the female body. The data also highlighted a paradox in digital health: despite 92 percent of respondents believing telehealth is vital for healthy aging, a mere 11 percent feel that current digital tools give them a true sense of control over their health journey.

This lack of tailored solutions is particularly concerning given that women face unique health challenges as they age. Women represent 80 percent of all autoimmune diagnoses and disproportionately suffer from chronic fatigue and cognitive symptoms like brain fog, especially during the transitions of perimenopause and menopause.

“As the telehealth market for treatments like NAD+ and glutathione becomes increasingly fragmented and expensive, women are being left behind,” said Monica Cepak, CEO of Wisp, in a statement. “Women are navigating complex hormonal transitions and immune issues that don’t fit into a standard biohacking framework. We’re translating complex science into clear, clinician-guided plans that support women long before something escalates.”

The Science Behind the Treatments

Wisp’s initial offering is built on a foundation of therapies gaining traction for their role in cellular health and immune modulation. The goal is to move beyond surface-level treatments and address the biological drivers of aging.

• Glutathione: Often called the body's "master antioxidant," glutathione is crucial for neutralizing free radicals and reducing oxidative stress, a key factor in cellular aging. Levels of this vital molecule naturally decline with age, and supplementation is believed to support cellular repair, enhance immune function, and improve skin health.

• NAD+ (Nicotinamide adenine dinucleotide): This coenzyme is a powerhouse of cellular metabolism, essential for converting food into energy within the mitochondria and for activating proteins that handle DNA repair. Like glutathione, NAD+ levels plummet with age, a decline linked to many age-related conditions. Boosting NAD+ is thought to improve mitochondrial function and enhance the body's innate repair mechanisms.

• Low-Dose Naltrexone (LDN): Used at a fraction of the dose prescribed for addiction treatment, LDN operates as an immune modulator. It is thought to temporarily block opioid receptors, which in turn prompts the body to increase its production of endorphins. This process may help regulate the immune system and reduce inflammation, making it a subject of interest for autoimmune conditions, which overwhelmingly affect women.

By offering these treatments through a telehealth platform, Wisp aims to make them more accessible and to provide the necessary medical oversight to ensure they are used safely and effectively.

Redefining Telehealth for Lifelong Wellness

This new vertical represents a significant evolution in Wisp's business model. Having built a user base of 1.8 million patients by providing discreet and rapid access to care for concerns like birth control, UTIs, and STIs, the company is now shifting its focus toward proactive, lifelong health management.

The new service operates on an asynchronous consultation model, allowing patients to communicate with clinicians on their own schedule, without the need for a live video appointment. This is followed by continuous clinician oversight and personalized adjustments to treatment plans, creating a more dynamic and supportive patient experience than a one-off prescription.

The strategic pivot is about fostering a long-term relationship with patients, guiding them through various life stages beyond traditional reproductive years.

"We are helping women take control of their healthspan, not just their lifespan,” stated Dr. Shannon Chatham, Medical Director at Wisp. “This isn’t about chasing trends, it's about providing evidence-based, sustainable care that meets the real needs of women as they age."

A Calculated Move in a Competitive Space

Wisp's expansion is not just a clinical development but a shrewd business move. The company has demonstrated impressive growth, achieving profitability and an annualized revenue run-rate of over $78 million as of mid-2024. Majority-owned by WELL Health Technologies Corp., Wisp has established itself as the largest pure-play women's telehealth provider in the U.S.

While competitors like Nurx, Maven Clinic, and Tia operate in the women's health space, Wisp's new vertical carves out a distinct niche. It combines a direct-to-consumer model available in all 50 states with a specific focus on the underserved women's longevity market, moving far beyond the scope of its rivals. This positions Wisp to capture a new and potentially lucrative segment of the healthcare market.

The company's future roadmap indicates this is only the beginning. Wisp plans to introduce further programs for mitochondrial support, cognitive health pathways, menopause-adjacent longevity care, and advanced preventive diagnostics. By focusing on how women actually age, Wisp is making a bold play to become an indispensable partner in their health journey from puberty to post-menopause and beyond.